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Abstract: Age is one of the strongest predictors of cardiovascular disease (CVD) risk. Treatment 
with statins can significantly reduce CVD events and mortality in both primary and secondary 
prevention. Yet despite the high CVD risk among the elderly, there is underutilization of statins 
in this population (ie, the treatment-risk paradox). Few studies have investigated the use of 
statins in the elderly, particularly for primary prevention and, as a result, guidelines for treating 
the elderly are limited. This is likely due to: uncertainties of risk assessment in older individu-
als where the predictive value of individual risk factors is decreased; the need to balance the 
benefits of primary prevention with the risks of polypharmacy, health care costs, and adverse 
medication effects in a population with decreased life expectancy; the complexity of treating 
patients with many other comorbidities; and increasingly difficult social and economic concerns. 
As life expectancy increases and the total elderly population grows, these issues become increas-
ingly important. JUPITER (Justification for the Use of statins in Prevention: an Intervention 
Trial Evaluating Rosuvastatin) is the largest primary prevention statin trial to date and enrolled 
a substantial number of elderly adults. Among the 5695 JUPITER participants $70 years of 
age, the absolute CVD risk reduction associated with rosuvastatin was actually greater than 
for younger participants. The implications of this JUPITER subanalysis and the broader role 
of statins among older adults is the subject of this review.
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Introduction
Cardiovascular disease (CVD) is the leading cause of death for both men and women 
in the US.1 In addition to causing significant mortality and morbidity, CVD is respon-
sible for a very large portion of medical spending. CVD accounts for the most annual 
hospital discharges of the 10 leading diagnostic groups (6.2 million in 2006), and the 
direct costs of CVD are estimated to be $324.1 billion in the US in 2010.1 The benefits 
for the appropriate use of evidence-based preventive therapies are widespread, and 
include reductions in CVD events, disability, and health care expenditure (ie, costly 
hospitalizations and institutionalizations), as well as improvement in quality of life. 
Thus, strategies for optimizing the prevention and treatment of CVD in the elderly are 
of paramount importance from both the individual and societal perspectives.2
It has long been acknowledged that increasing age is one of the strongest risk 
factors for the development of CVD. The prevalence of CVD increases with age, 
from 15% in men and 9% in women aged 20–39 years to 79% in men and 85% in 
women aged 80+ years.1 As such, higher age categories are the primary determinants of 
increased risk in global risk assessment tools, such as the Framingham Risk Score (FRS), Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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which take into account age, gender, total and high-density 
lipoprotein cholesterol (HDL-C), smoking, and blood pressure.3 
The National Cholesterol Education Program (NCEP) Adult 
Treatment Panel (ATP)-III guidelines use the FRS to set lipid 
treatment guidelines based on the FRS-determined 10-year 
global risk for coronary heart disease (CHD).3 However, the 
FRS was designed for those ,80 years of age and becomes less 
accurate in the elderly population. Furthermore, limitations of 
the FRS scoring system for underestimating CVD risk in other 
populations have been acknowledged as well.4–6
Age is perhaps the strongest prognostic factor in clinical 
medicine, and age commonly dictates treatment plans 
because of marked biologic differences between age groups. 
The division of people into distinct age groups allows for 
more focused study and development of specific clinical 
guidelines. In most developed countries, the age at which 
people are considered “elderly” has been conventionally 
set at 65 years, which is often associated with retirement 
age or the age when one begins to receive pension benefits 
in that country. The physiologic changes, as a result of 
aging, occur along a continuum rather than in discrete age 
groups, and life expectancies continually change as medical 
advances are made. This has resulted in an evolving concept 
of the “elderly”. Some have suggested further dividing the 
elderly into three groups, ie, 65–74 years, 75–85 years, 
and $85 years, for better understanding of the different 
biologic processes that occur with age.7
Elderly adults with CVD, or at increased risk for CVD, are 
an increasingly challenging subset of the population to treat, 
because they are more likely to have comorbid conditions, 
atypical presentations, and unfavorable outcomes compared 
with their younger counterparts.8 Evidence-based medicine 
for CVD prevention in subjects over the age of 80 years is 
limited and frequently extrapolated from studies of younger 
individuals.9
Multiple observational and clinical trials have confirmed 
that increased low-density lipoprotein cholesterol (LDL-C) 
levels are associated with greater risk for new-onset CHD 
among people without a history of CHD and increased 
recurrent coronary events in people with established CHD. 
The development of statins, or HMG-CoA reductase 
inhibitors, has greatly added to the arsenal of medical 
therapy for the treatment and prevention of CVD, and has 
contributed to the reduction of CVD-related mortalities. 
The NCEP ATP-III recommends that, for high-risk patients, 
the treatment LDL-C goal is ,100 mg/dL, but that an LDL-C 
goal of ,70 mg/dL is a therapeutic option for those at very 
high risk or those with baseline LDL-C of ,100 mg/dL.3 
Unfortunately, treatment gaps are well documented; a 2003 
national survey found that only 57% of high-risk individu-
als with CHD or risk equivalent achieved the recommended 
LDL-C goal of ,100 mg/dL and only 18% achieved the 
goal of ,70 mg/dL.10
However, few studies have investigated the use of statins 
in the elderly, particularly for primary prevention and, 
as a result, guidelines for treating the elderly are limited. 
JUPITER (Justification for the Use of statins in Preven-
tion: an Intervention Trial Evaluating Rosuvastatin) is the 
largest primary prevention statin trial to date, and enrolled 
a substantial number of elderly adults.11 The implications of 
JUPITER, the role of rosuvastatin for CVD risk reduction 
in the elderly, and the broader role of statins among older 
adults are discussed here. For this review, the search terms 
“rosuvastatin”, “statins”, “elderly”, “older adults”, and “car-
diovascular disease” were entered into PubMed, and selected 
clinical trials and observational studies (based on size, impor-
tance to the field, and direct relevance to this review topic) 
were chosen by the authors to present in this review.
Pharmacology, mode of action, and 
pharmacokinetics of rosuvastatin
There are several ways in which statins improve the lipid 
profile. Statins work by inhibiting the actions of HMG-CoA 
reductase, an enzyme responsible for the conversion of HMG-
CoA to mevalonate in the rate-limiting step of intracellular 
cholesterol biosynthesis. This leads to decreased LDL-C and 
very-low-density lipoprotein (VLDL-C) synthesis.12 With 
decreased intracellular stores of cholesterol, cells upregulate 
the expression of LDL receptors on the surface of the liver 
and increase the uptake of LDL-C and VLDL-C from the 
circulation. Most of the statins also modestly raise HDL-C. 
The exact mechanisms are unclear, but could possibly involve 
decreasing the fractional catabolic rate of apolipoprotein A-I, 
increasing apolipoprotein A-I production, and/or inhibiting 
cholesteryl ester transfer protein activity.
Statin use often results in clinical benefits greater than 
what might be expected from changes in lipid levels alone. 
This is due to possible pleiotropic effects of statins, which 
include improving endothelial function, stabilizing athero-
sclerotic plaques, decreasing oxidative stress and inflamma-
tion, and inhibiting the thrombogenic response.13
Rosuvastatin is a highly effective statin medication that 
is the most potent of its class in reducing LDL-C and raising 
HDL-C levels. In STELLAR (Statin Therapies for Elevated 
Lipid Levels compared Across doses to Rosuvastatin)14 
and the MERCURY (Measuring Effective Reductions in Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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Cholesterol Using Rosuvastatin therapY) I–II trials,15,16 
patients in the rosuvastatin groups were able to achieve 
greater reduction in LDL-C than patients on other statins. 
Because multiple clinical trial results suggest that greater 
lowering of LDL-C and lower LDL-C level treatment goals 
are beneficial in populations with existing CVD or at risk 
of it,17–20 the role of more potent statins, such as rosuvastatin, 
might increase. On the other hand, the second most potent 
statin, atorvastatin, will likely be available as a generic 
medication in 2012.
The increased LDL-C-lowering potency of rosuvastatin 
over other statins can be attributed to its unique chemical 
properties that give it the highest affinity for HMG-CoA 
reductase.12 A fluorinated phenyl group and a polar methyl-
sulfonamide group on rosuvastatin provides multiple sites of 
activity against the enzyme. Rosuvastatin is also hydrophilic 
and does not require metabolic conversion to a water-soluble 
molecule for elimination, which reduces the number of 
drug-drug interactions that other more hydrophobic statins 
encounter. In healthy volunteers, 90% of orally administered 
[14C]-radiolabeled rosuvastatin was recovered in feces 
in its unmetabolized form. Lastly, both rosuvastatin and 
atorvastatin have enhanced binding enthalpies for HMG-CoA 
reductase, due to formation of a hydrogen bond with the 
enzyme that causes greater inhibition of the enzyme.
Rosuvastatin has an oral bioavailability of 20%, similar 
to that of atorvastatin, pravastatin, and fluvastatin, with 
peak plasma concentrations reached 3–5 hours after oral 
administration and an elimination half-life for rosuvastatin 
of approximately 19 hours.12 Importantly, there were no 
significant differences in plasma rosuvastatin concentrations 
or reductions in LDL-C levels relative to age or gender of 
the subjects. Rosuvastatin is predominantly cleared by the 
hepatic route, with only minimal renal clearance (28%), and 
the dose does not need to be adjusted in those with mild to 
moderate renal impairment.21
Statins for secondary prevention  
in older adults
People with established CHD are at high risk for recur-
rent events. The use of LDL-C-lowering therapy has been 
shown to reduce the incidence of recurrent coronary events 
in people with established CHD in multiple secondary 
prevention trials, even before the development of statins.22 
Since the introduction of statins, secondary prevention 
trials with statins, such as 4S (the Scandinavian Simvastatin 
Survival Study),23 the CARE (Cholesterol And Recurrent 
Events) study,24 the LIPID (Long-term Intervention with 
Pravastatin in Ischemic Disease) study,25 and the HPS (Heart 
Protection Study)26 have shown that participants with CHD 
and/or diabetes treated with simvastatin or pravastatin had 
decreased incidences of major coronary events, revascular-
ization, coronary mortality, strokes, and total mortality.
HPS, which enrolled 9839 participants aged ,65 years, 
4891 participants aged 65–70 years, and 5806 participants 
aged .70 years, showed that the proportional reduction in 
event rates was similar across age categories.26 The study 
demonstrated that statins had substantial benefit in older 
age as well as in middle age for secondary prevention. In 
the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evalu-
ation and Infection Therapy – Thrombolysis in Myocardial 
Infarction 22) study,19 intensive lipid-lowering statin therapy 
was found to be superior to standard statin therapy in protect-
ing against death or major cardiovascular events in patients 
who suffered a recent acute coronary syndrome and also 
found that these patients benefited from further lowering 
of LDL-C. In this trial, there was no significant interaction 
for treatment effect heterogeneity across the age subgroups 
(,65 years or $65 years).
While the results for older patients .65 years were 
analyzed in many clinical trials as part of age-specific 
subgroup analysis, two secondary prevention studies, 
ie, PROSPER (PrOspective Study of Pravastatin in the Elderly 
at Risk) and SAGE (Study Assessing Goals in the Elderly) 
enrolled only older adults. PROSPER27 was conducted to 
evaluate the role of pravastatin 40 mg/day compared with 
placebo in reducing coronary and cerebral events in elderly 
patients aged 70–82 years (mean baseline age 75 years) with 
pre-existing vascular disease or who were at high risk of 
vascular disease and stroke; most would say this represents 
a combination of primary and secondary prevention.
PROSPER randomized 5804 participants within this older 
age range and having total plasma cholesterol 155–350 mg/dL 
and triglyceride levels ,200 mg/dL to treatment with pravas-
tatin or placebo. After a mean follow up of 3.2 years, it was 
found that participants in the pravastatin group had 34% lower 
LDL-C levels compared with placebo and had a statistically 
significant 15% relative risk reduction in the incidence of 
coronary death, nonfatal myocardial infarction, and fatal 
or nonfatal stroke. However, there were more new cancer 
diagnoses in the pravastatin group compared with placebo. 
Subsequent large meta-analyses of statin trials did not confirm 
an increase risk of cancer associated with statin treatment.28
In SAGE,29 researchers compared the effects of intensive 
versus moderate statin therapy in 893 older patients 
aged 65–85 years (mean age 72 years) with one or more Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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episodes of myocardial ischemia during 48-hour ambulatory 
electrocardiography. The participants were randomized to 
atorvastatin 80 mg/day or pravastatin 40 mg/day. While there 
was no difference between the two groups in the primary 
endpoint of duration of ischemia on ambulatory monitoring at 
12 months, intensive atorvastatin therapy was associated with 
greater reductions in cholesterol, a trend toward fewer major 
acute cardiovascular events (hazard ratio [HR] 0.71; 95% CI 
0.46−1.09; P = 0.114), and statistically significant reduction 
in all-cause death (HR 0.33; 95% CI 0.13–0.83; P = 0.014). 
The authors concluded that these findings, together with 
the increased cardiovascular risk in the elderly population, 
suggest that intensive statin therapy should be considered in 
elderly patients with CHD.
Clinical trials frequently have multiple exclusion criteria 
and, thus, elderly patients with many comorbidities (such as 
renal failure or insufficiency, etc) may be excluded from par-
ticipation. The efficacy of statin use for secondary prevention 
among the very elderly has been examined in a real-world 
clinical registry setting. Gransbo et al studied 14,907 patients 
over the age of 80 years who were admitted with an acute 
myocardial infarction in the Register of Information and 
Knowledge About Swedish Heart Intensive Care Admissions 
(RIKS-HIA) and followed for a median of 296 days (maximum 
of five years).30 Among the very elderly patients receiving 
statin therapy at discharge, there was a 45% lower risk of all-
cause mortality (relative risk [RR] 0.55, 95% CI 0.51–0.59). 
Mortality reduction with statin use was similar when deaths 
within 14 days or within 365 days of the index event were 
excluded from analysis. This real-world data confirms that, 
even among the very elderly, a CVD risk reduction benefit is 
seen even within a short time period, and supports close con-
sideration of statins for high-risk patients, regardless of age.
Statins for primary prevention  
in older adults
Multiple clinical trials have suggested a benefit of statins in 
primary prevention, although these trials generally enrolled a 
younger population. WOSCOPS (West of Scotland Coronary 
Prevention Study) studied men (mean baseline age 55 years, 
with an upper age limit of only 64 years) with moderate 
hypercholesterolemia on initial screening but no history 
of myocardial infarctions or cardiac revascularization.31 
Subgroup analyses showed that the relative reductions in 
CHD risk attributable to pravastatin therapy was not affected 
by age (,55 versus $55 years).
In the MEGA (Management of Elevated Cholesterol 
in the Primary Prevention Group of Adult Japanese) 
study,32 8214 patients, including men aged 40–70 years and 
postmenopausal women aged up to 80 years (mean baseline 
age 58 years) with hypercholesterolemia and no history of 
CHD or stroke were randomized to diet alone or diet plus 
pravastatin groups. At the mean follow-up of 5.3 years, 
assignment to pravastatin therapy conferred a 33% RR reduc-
tion in CHD. Subgroup analysis of the risk reduction of CHD 
with pravastatin did not show significant interactions in any 
subgroup, including age ,60 and $60 years.
The AFCAPS/TexCAPS (Air Force/Texas Coronary 
Atherosclerosis Prevention Study)33 randomized 6605 par-
ticipants aged 45–73 years with average total cholesterol 
and LDL-C and below-average HDL-C levels to lovastatin 
or placebo. The baseline mean age of the participants was 
58 years, with 21% older than 65 years. After a follow-up of 
5.2 years, participants in the lovastatin group were found to 
have LDL-C levels reduced by 25%, HDL-C levels increased 
by 6%, and a significant 37% RR reduction in the rate of 
first acute major coronary event, defined as the composite 
endpoint of fatal or nonfatal myocardial infarction, unstable 
angina, or sudden cardiac death. Further subgroup analysis 
based on gender-stratified median age (which was .57 years 
in men and 62 years in women) versus # median age did not 
show any significant differences in benefit with lovastatin 
in the two age groups. The authors concluded that there was 
no reason to believe older people did not benefit as much as 
younger ones from lovastatin therapy.
ASCOT (the Anglo-Scandinavian Cardiac Outcomes Trial) 
randomized 19,342 hypertensive patients aged 40–79 years 
(mean baseline age 63 years) with three other cardiovascular 
risk factors (ie, a higher risk primary prevention cohort) to 
one of two antihypertensive regimens. In ASCOT-LLA (the 
Lipid Lowering Arm of the study),34 10,305 of the hyperten-
sive patients not deemed to be hypercholesterolemic (with 
total nonfasting cholesterol ,250 mg/dL) were randomized 
to additional treatment with atorvastatin 10 mg or placebo. 
The trial was planned for follow-up in five years, but was 
prematurely stopped after a median follow-up of 3.3 years due 
to a significant reduction in the primary endpoint of nonfatal 
myocardial infarction and fatal CHD for atorvastatin com-
pared with placebo (HR 0.64, 95% CI 0.50–0.83, P = 0.0005). 
The effect of atorvastatin on the primary endpoint was not 
significantly different in any prespecified subgroup, including 
those specified as younger (#60 years) or older (.60 years). 
Of note, in PROSPER,27 there was no reduction in strokes 
seen for patients .70 years with pravastatin. However, a 
subanalysis of ASCOT34 did find that stroke prevention with 
atorvastatin was similar among the 2416 patients .70 years Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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compared with those #70 (31% versus 24% relative stroke 
reduction).
JUPITER trial of statins  
in primary prevention
As described above, previous primary prevention trials 
required hyperlipidemia or low HDL-C at enrollment. 
JUPITER,11 the largest primary prevention statin trial to date, 
was a multicenter, randomized, double-blind, placebo-con-
trolled trial enrolling men $50 years and women $60 years 
(median baseline age 66 years) who had no history of CVD, 
no hypercholesterolemia (LDL-C level ,130 mg/dL), a 
high-sensitivity C-reactive protein (hsCRP) level $2.0 mg/L, 
and a triglyceride level ,500 mg/dL at the initial screen-
ing visit. After an initial four-week run in phase to identify 
individuals with good compliance, the eligible participants 
were randomized to receive either rosuvastatin 20 mg daily, 
or matching placebo. Of the 89,890 people screened for 
enrollment, 17,802 were eligible to participate (of which the 
majority were excluded for not meeting the LDL-C or hsCRP 
criteria). Compared with previous trials, JUPITER enrolled 
an older population with no upper age limit.
JUPITER was terminated after a median follow-up of 
1.9 years due to a statistically significant reduction in the pri-
mary endpoint of myocardial infarction, stroke, arterial revas-
cularization, hospitalization for unstable angina, or death from 
cardiovascular causes in the rosuvastatin group compared with 
placebo (HR 0.56, 95% CI 0.46–0.69, P , 0.00001). The 
rosuvastatin group had a 50% lower median LDL-C level and 
a 37% lower median hsCRP level than the placebo group at 
12 months that persisted throughout the study period. Based 
on Kaplan-Meier estimates, the number needed to treat (NNT) 
with rosuvastatin for two years to prevent the occurrence of 
one primary endpoint is 95. Extrapolated out to five years, 
the NNT for the primary endpoint is 25, and including venous 
thromboembolic events, the NNT is only 18.35
In subgroup analyses, the authors found no evidence for 
heterogeneity in the results for any subgroup, with similar 
relative hazard reductions in the rosuvastatin group noted in 
subgroups according to age (#65 and .65 years), gender, 
race or ethnic group, region of origin, FRS, and status with 
regard to traditional risk factors.11 For subjects with elevated 
hsCRP levels but no other major risk factor other than the 
increased age at enrollment required for eligibility, the benefit 
of rosuvastatin was similar to that for higher risk subjects 
(HR 0.63, 95% CI 0.44–0.92, P = 0.01).
A secondary analysis of JUPITER examined the 5695 
participants $70 years at baseline to evaluate the efficacy 
and safety of rosuvastatin in older adults.36 The authors chose 
the cutpoint of age 70 years because of the lack of data on the 
use of statins for primary prevention in that age group. This 
elderly group comprised 32% of the total number of trial 
participants, but accounted for 49% of the 393 confirmed 
primary cardiovascular endpoints. This elderly group was 
also noted to have a different profile of other cardiovascular 
risk factors when compared with the younger participants, 
with higher percentages of women and individuals with 
hypertension, and lower percentages of obesity and cigarette 
smoking in the elderly group.
The reduction in lipid levels and hsCRP levels seen in the 
rosuvastatin group was similar in the elderly group and the 
younger group. The median LDL-C levels in the rosuvastatin 
group (54 mg/dL and 55 mg/dL in older and younger par-
ticipants, respectively) were half those in each age group 
that received placebo. The median hsCRP levels (2.3 and 
2.2 mg/L in older and younger participants, respectively) 
were nearly 36% lower in the rosuvastatin versus placebo 
group, separately in each age group.
Rates of the primary endpoint among JUPITER 
participants $70 years were 1.22 and 1.99 per 100 person-years 
of follow-up in the rosuvastatin and placebo groups, respectively 
(HR 0.61, 95% CI 0.46–0.82). This RR reduction is somewhat 
more modest than compared with younger individuals aged 
50–69 years (HR 0.51, 95% CI 0.38–0.69), which is consistent 
with a meta-analysis of observation studies reporting that a 
1 mmol/L (39 mg/dL) lower total cholesterol level was asso-
ciated with a 56% reduction (CI 52%–58%) in the hazard of 
death from ischemic heart disease at age 40–49 years, but a 17% 
reduction (CI 15%–19%) at age 70–89 years.37 Yet, in JUPITER, 
there was no statistically significant interaction between age and 
treatment effect for any outcome (P . 0.10 for each).
Furthermore, when combined with the fact that the 
elderly group had higher rates of cardiovascular events, 
the absolute reduction in the incidence of the primary 
endpoint associated with rosuvastatin was actually 48% 
greater (0.77 versus 0.52 events per 100 person-years) in 
the elderly group compared with the younger group.36 The 
estimated NNT of elderly persons for four years to prevent 
one primary endpoint was 24 (CI 15–57) compared with 
36 (CI 23–77) in the younger group. There were similar 
hazard reductions in both elderly men and women, and no 
significant heterogeneity was observed across subgroups 
among the elderly participants.
Older participants in the JUPITER study did have higher 
rates of adverse events (including muscle weakness, newly 
diagnosed cancers, renal disorder, gastrointestinal or hepatic Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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disorder, and bleeding) compared with younger adults. 
However, these adverse effects were not more common 
in older patients treated with rosuvastatin compared with 
placebo (P . 0.10 for all adverse events), indicating the 
safety of rosuvastatin treatment in this age group. However, 
it should be remembered that the mean follow-up for this 
trial was only about two years.
Of note, several limitations of the overall JUPITER 
study design have been acknowledged,38 including the pos-
sibility that the premature termination of the trial might 
have exaggerated the benefits.39 However, an independent 
review by the US Food and Drug Administration of the 
JUPITER trial concluded that any potential overestimate of 
the RR reduction due to early stopping would be minimal 
and not change the overall study implications.40 Also, only 
those with elevated hsCRP $2 mg/L were enrolled, so it 
still remains unclear whether all older adults, regardless of 
hsCRP level, might benefit from statin therapy by virtue of 
increased baseline risk.
Using data from the National Health and Nutrition Exami-
nation Survey 1999–2004, we estimated that 6.5 million addi-
tional adults, not currently eligible for statin therapy by the 
NCEP ATP-III criteria, could potentially be candidates for 
initiating statins according to the JUPITER criteria.41 Thus, 
using the JUPITER eligibility strategy, an estimated 260,000 
CVD events could be prevented in the US at five years.41 The 
fourth Adult Treatment Panel is currently convening to weigh 
the evidence from the more recent statin clinical trials that 
have taken place since 2004, and updated lipid guidelines 
are anticipated to be released in 2011.
Rosuvastatin for prevention  
in special populations
On the other hand, two important studies, ie, AURORA 
(A study evaluating the Use of Rosuvastatin in patients 
requiring Ongoing Renal dialysis: an Assessment of survival 
and cardiovascular events) and CORONA (Controlled 
Rosuvastatin Multinational Trial in Heart Failure), evaluat-
ing the efficacy of rosuvastatin in specific populations found 
that while rosuvastatin did reduce the levels of LDL-C and 
hsCRP, there was no difference in the rate of primary end-
points in the rosuvastatin groups compared with placebo.
Several studies have shown that patients undergoing 
maintenance hemodialysis have an increased risk of 
CVD, and observational studies have suggested that statin 
therapy can have survival benefits in patients undergoing 
hemodialysis. AURORA42 was a prospective trial that ran-
domized 2776 patients, aged 50–80 years (mean baseline age 
64 years), who were undergoing maintenance hemodialysis 
for advanced renal failure to receive rosuvastatin 10 mg 
daily or placebo. After three months of treatment, patients 
randomized to the rosuvastatin group had LDL-C levels that 
were 43% lower than their baseline level as compared with 
only a 2% reduction from baseline in the placebo group. The 
median hsCRP level decreased by 12% in the rosuvastatin 
group (by 0.65 mg/L, versus an increase of 0.21 mg/L in the 
placebo group, P , 0.001).
After a median follow-up of 3.8 years, the primary end-
point of death from cardiovascular causes, nonfatal myocardial 
infarction, or nonfatal stroke occurred in 396 patients in the 
rosuvastatin group (0.2 events per 100 patient-years) versus 
408 patients in the placebo group (9.5 events per 100 patient-
years), with no significant effect of treatment (HR 0.96, 95% 
CI 0.84–1.11, P = 0.59). The lack of an effect of rosuvastatin 
therapy on the primary endpoint was consistent in all the pre-
specified subgroups, including patients younger than 65 years 
and those aged $65 years.
These findings suggest that the CVD process in patients 
undergoing hemodialysis differs from that in other patient popu-
lations. In the general population, a majority of cardiovascular 
events are coronary events such as myocardial infarctions. In 
the hemodialysis population, however, only approximately 25% 
of cardiovascular events are myocardial infarctions.43 Rather, 
heart failure, sudden cardiac death, and arrhythmias predomi-
nate in this population. Therefore, the anti-inflammatory and 
lipid-lowering effects of statins may not benefit a population 
in which myocardial infarctions do not predominate.
CORONA44 investigated the use of rosuvastatin in older 
patients with systolic heart failure, a population also gener-
ally excluded from statin trials. The study randomized 5011 
patients aged at least 60 years (mean baseline age 73 years, 
with 41% at least 75 years) with New York Heart Asso-
ciation Class II, III, or IV ischemic systolic heart failure 
to rosuvastatin 10 mg daily or placebo. After a median 
follow-up of 32.8 months, patients in the rosuvastatin group 
had decreased levels of LDL-C (45% difference between 
groups, P , 0.001) and hsCRP (37% difference between 
groups) compared with placebo. However, there was no 
statistically significant decrease in the primary outcome, 
that included death from cardiovascular causes, nonfatal 
myocardial infarction, or nonfatal stroke (HR 0.92, 95% CI 
0.83–1.02, P = 0.12). On the other hand, there was a statisti-
cally significant reduction in the number of hospitalizations 
for cardiovascular causes in the rosuvastatin group compared 
with the placebo group (P , 0.001), which was a secondary 
endpoint for this trial.Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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The authors of the study had hypothesized that statin 
use would stabilize coronary plaques and reduce myocar-
dial ischemia and infarction, and thereby decrease the rate 
of sudden death in patients with ischemic heart failure,   
a population in which half of the sudden deaths are caused 
by plaque rupture. While it is unclear why treatment with 
rosuvastatin did not decrease the rate of the primary outcome, 
the authors suggested that alternative mechanisms of death, 
such as pump failure rather than atherosclerotic causes, 
effects of other drugs the patients were on, and the need for a 
longer follow-up period to see beneficial effects of treatment 
as possible explanations.
A post hoc analysis from CORONA did suggest a signifi-
cant interaction by hsCRP status (P interaction = 0.026) with 
rosuvastatin benefitting those with hsCRP $2 mg/L but not 
those with low hsCRP.45 Furthermore, an economic analysis 
of the overall CORONA cohort, including both the primary 
outcome and the secondary outcome of hospitalizations, did 
find that the overall reduction in CVD events with rosuvastatin 
partially offset the costs of rosuvastatin treatment by 44%, 
thus finding rosuvastatin treatment to be a cost-effective treat-
ment for older patients with systolic heart failure.46
Risk-treatment paradox  
in the elderly
Elderly patients have the highest CVD risk, and yet there is 
an underutilization of statin therapy in this population (ie, 
the treatment-risk paradox).47,48 Using registry data of nearly 
400,000 patients .66 years in Ontario who had a prior history 
of CVD or diabetes, the adjusted likelihood of statin prescrip-
tion was 6.4% lower for each one year in age and each 1% 
increase in predicted three-year mortality risk.49 Gnavi et al 
looked at prescribing practices of statins for residents of 
Torino, Italy, aged 30–85 years in 2001–2002 with a hospital 
discharge diagnosis of ischemic heart disease by comparing 
with the regional database for drug prescriptions. The authors 
found that, among those .74 years of age, statin prescription 
rates were 40% lower than for younger individuals.50
A more recent US survey conducted in 2005–2006 
reviewed medical records from 4964 primary care visits 
for patients aged 55–80 years with cerebrovascular disease, 
ischemic heart disease, peripheral arterial disease, aortic 
aneurysms, diabetes mellitus, or any two risk factors (hyper-
lipidemia, hypertension, or smoking). The authors found 
that only 38% were prescribed a statin, a far lower amount 
than would be anticipated from their comorbidities.51 This 
problem of undertreatment in the elderly is not exclusive to 
statin therapy, because many proven therapies, including 
thrombolytic therapy52 and beta-blockers,53 have been 
reported to be underutilized in the elderly presenting with 
acute myocardial infarction.
Resistance to statin use  
in the elderly
As described above, in randomized controlled trials of both 
secondary and primary prevention, supported by registry 
data, statins have been shown to reduce CHD events and in 
some cases all-cause mortality. This finding applies across 
nearly all available studies, with the possible exception of 
highly specialized populations, such as systolic heart failure 
and end-stage renal disease requiring hemodialysis.
While the evidence for statins for secondary prevention in 
the elderly is more established (despite their underutilization), 
there are fewer primary prevention studies dedicated to 
enrolling large numbers of elderly patients, and thus data 
to support guidelines in this age group are limited. This is 
possibly due in part to the increasing uncertainties of risk 
assessment in older individuals as the predictive value of 
risk factors declines. Other issues to take into consideration 
include the increased need to balance the benefits of primary 
prevention with the risks of polypharmacy, health care costs, 
and adverse medication effects in a population with decreased 
life expectancy, increased number of coexisting diseases, 
and more difficult social and economic situations. As the 
population of the elderly continue to increase with medical 
advances, these issues are becoming more important.
Of note, a small but statistically significant increased risk of 
incident diabetes has been reported with statin therapy compared 
with placebo in a recent large meta-analysis of statin clinical 
trials (odds ratio 1.09, 95% CI 1.02–1.17), a risk that was high-
est in trials with older participants such as those in PROSPER 
and JUPITER.54 This translated to one new case of diabetes per 
1000 person-years of treatment, but extended over four years, 
nine vascular events would be prevented for each new case of 
diabetes. Thus, it is generally thought that the risk of incident 
diabetes is low when compared with the significant reduction 
in CVD events. However, some authors have suggested that the 
risk/benefit ratio of treatment may not be as favorable in subjects 
with a propensity to develop diabetes, such as the elderly, and 
warrants further study.55
Low to moderate doses of statins do appear to be well 
tolerated in the elderly. The safety of statin therapy in the 
elderly can be enhanced by avoiding concomitant use of P450 
inhibitors, chronic immunosuppressive therapy (cyclosporine), 
or fibrates (gemfibrozil), and by limiting concomitant use 
of niacin and alcohol intake (less than two drinks daily). Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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Obviously, laboratory screening for renal, liver, and thyroid 
function should be performed before initiation of statin 
therapy. Consider starting statin therapy at lower doses and 
titrating slowly (toxicity is dose-related). If there is severe 
medical illness, major surgery, or major trauma, the discontinu-
ation of statin therapy until recovery can be considered.
Conclusion
In summary, there is a need for further study regarding the 
role of statin therapy for primary prevention in the elderly, 
especially for those without overt hyperlipidemia who do not 
currently meet the NCEP-ATP III guidelines for initiation 
of statin therapy and among the elderly with well controlled 
blood pressures.56 Furthermore, the risk of new-onset diabetes 
with statin therapy should be evaluated more closely in the 
elderly population.
However, in the absence of medical contraindications, 
at this time the authors feel there is sufficient evidence to 
support the recommendation for use of statin treatment 
in most elderly patients with risk profiles similar to those 
enrolled in prior primary and secondary prevention trials.
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